The Long Run with Luke Timmerman

Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."

Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.

Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.

Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.

Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.

Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report

Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.

Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.

Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.

Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.

Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.

Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.

Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.

Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.

John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.

Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.

Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.

Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.

David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.

Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.

David Schenkein, general partner at GV, on investing in the future of biotech.

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.

Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.

Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.

Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.

Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.

Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.

Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.

David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.

Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.

David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.

Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.

Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.

Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.

Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.

Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.

Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.

Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.

Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.

Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.

Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.

Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.

Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders

Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.

Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.

Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.

Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.

Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.

Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.

Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.

Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.

Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.

Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.

Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.

David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.

Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.

Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.

Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.

DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.

Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.

Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.

Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.

Aetna Wun Trombley, CEO of Lycia Therapeutics, on extracellular protein degraders.

Samantha Truex, CEO of Upstream Bio, on a new approach to treating severe asthma and other inflammatory diseases.

Tim Lu, CEO of Senti Biosciences, on developing gene circuits for cell therapy.

Jo Viney, CEO of Seismic Therapeutic, on discovering new treatments for autoimmune disease.

Ivan Liachko, CEO of Seattle-based Phase Genomics, on assembling accurate genomes and interactomes. He also discusses immigrating from Ukraine as a child, and what brought him and his family to the US.

Dr. Sanduk Ruit of the Tilganga Institute in Kathmandu on restoring eyesight with affordable cataract surgery for the developing world.

Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, on precision neuroscience drug development.

Rahul Singhvi, CEO of Resilience, on rethinking the model for manufacturing of advanced biologics, gene and cell therapies.

Chris Gibson, co-founder and CEO of Recursion, on using new tools to industrialize drug discovery.

Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations.

Bernat Olle, CEO of Vedanta Biosciences, on developing microbiome therapeutics.

Ray Stevens, CEO of ShouTi, on structural biology driven drug discovery.

Michele Andrasik, a clinical health psychologist at the Fred Hutchinson Cancer Research Center, on improving community outreach and diversity in clinical trials.

Derrell Porter, CEO of CellEvolve, on a new approach to commercializing cell therapies.

Praveen Tipirneni, CEO of Morphic Therapeutic, on targeting integrins with small molecules.

Bassil Dahiyat of Xencor on antibody engineering and company building.

Vineeta Agarwala, general partner with Andreesen Horowitz's bio fund, on investing in therapeutics, diagnostics and digital health.

Nello Mainolfi, CEO of Kymera Therapeutics, on targeted protein degrading small molecule drugs.

Jeff Bluestone, CEO of Sonoma Biotherapeutics, on engineered T-reg cell therapies for autoimmunity.

Ken Song, CEO of RayzeBio, on targeted radiopharmaceuticals for cancer.

David Baltimore, professor emeritus at Caltech, reflects on a life in science.

Tony Kulesa of Petri.bio on fostering founder-led biotech companies

Christian Henry, CEO of PacBio, on long read DNA sequencing applications.

Keolu Fox, assistant professor at UC San Diego, on genome sequencing of indigenous populations.

Mara Aspinall of Arizona State University on diagnostics and COVID-19.

John Evans, CEO of Beam Therapeutics, on base editing technology for therapeutics.

Ep96: Julie Grant and Sam Blackman on Cancer Drugs for Kids

Sue Desmond-Hellmann on becoming a physician-scientist and biotech industry leader.

Jenny Rooke of Genoa Ventures on investing in biology & technology.

Ep93: Jay Bradner of Novartis & Andy Plump of Takeda on Mentoring Young Scientists

NanoString Technologies CEO Brad Gray on tools for spatial biology.

Daphne Zohar, CEO of Puretech Health, on starting biotech companies.

James Sabry, global head of pharma partnering for Roche, on partnering in a time of scientific abundance.

Emily Leproust, co-founder and CEO of Twist Bioscience, on DNA Synthesis at Scale

Amy DuRoss, CEO of Vineti, on software and logistics for cell and gene therapy.

Bob Nelsen of ARCH Venture Partners on long-term trends in biotech investing.

Sekar Kathiresan, co-founder and CEO of Verve Therapeutics, on a gene edited single shot for cardiovascular disease.

Luhan Yang, CEO of Qihan Bio, on CRISPR editing for organ transplants.

Steve Paul, CEO of Karuna Therapeutics, on neuropsychiatric drug development.

David Lee, CEO of Servier Pharma, on a nonprofit model.

Andrew Farnum, CEO of Variant Bio, on drug discovery based on rare genetic traits.

Simba Gill, CEO of Evelo Biosciences, on microbiome therapies.

Peter Kolchinsky of RA Capital on making drugs affordable, and keeping incentives for drug discovery.

Daphne Koller, CEO of insitro, on machine learning for drug discovery

Pearl Huang, CEO of Cygnal Therapeutics, on Exoneural Cancer Biology

Jennifer Petter, CSO of Arrakis Therapeutics, on small molecule drugs for RNA targets

Otello Stampacchia on becoming a biotech venture capitalist.

Rosana Kapeller, CEO of ROME Therapeutics

Abe Ceesay, CEO of Tiburio Therapeutics

Ep73: Kevin Ness on Digital Genome Engineering by Timmerman Report

Ted Love, CEO of Global Blood Therapeutics, on Racial Inequity

Takeda R&D president Andy Plump on fighting COVID19 and racism.

Nina Kjellson forging a path in biotech venture capital.

Ep69 of The Long Run with virologist Larry Corey

Emma Hodcroft on NextStrain and viral evolution

George Scangos of VIR on neutralizing antibodies for SARS-CoV-2

Mike Pellini on COVID19 diagnostic testing.

Leaders of EQRx, a company aspiring to make novel drugs at low prices.

Isabella is a Stage 4 lung cancer patient on a mission.

Jeremy Levin, chairman of BIO, on the perilous moment in politics.

Jane Grogan, CSO of Arsenal Bio, on programmable cell therapies.

Sanjiv Patel, CEO of Relay Therapeutics, computational drug discovery company.

Tim Mayleben, CEO of Esperion Therapeutics, on cholesterol-lowering meds.

David Baker, University of Washington protein designer.

Jigar Raythatha of Constellation Pharma on epigenetic drug development.

John Alam on Alzheimer's drug development.

Tim Springer of Harvard Medical School on his career in science and biotech.

Discussion on the new Henri Termeer biography.

CEO of Synlogic on developing synthetic biology-based drugs.

MIT biologist Phil Sharp on his early career.

Bruce Carter on developing a new tuberculosis drug.

Ted Love of Global Blood Therapeutics on a new drug for sickle cell disease

Joel Marcus, chairman of Alexandria Real Estate Equities, on building in biotech clusters.

Janelle Anderson on venture capital and off-the-shelf cell therapy at Century Therapeutics

Cindy Perettie of Foundation Medicine on genomic analysis for cancer.

Laura Shawver on synthetic biology engineering of cancer drugs.

Liz O'Day on metabolite signatures for predicting cancer drug response.

Jay Bradner, president of Novartis Institutes for Biomedical Research, on his journey from open biology advocate to pharma leadership.

Sheila Gujrathi, CEO of Gossamer Bio, immunologic drug developer

Sage Therapeutics CEO on psychiatric drug development.

Carolyn Bertozzi on becoming a chemical biologist/glycobiologist.

MIT's Bob Langer on his journey in science and entrepreneurship.

Serge Saxonov on the single-cell analysis revolution.

Julia Owens on pivoting, more than once, in a biotech startup.

The co-founders of Adaptive Biotechnologies on immune sequencing.

Bonnie Anderson of Veracyte on genomic diagnostics.

George Scangos on building an infectious disease company

Karen Akinsanya of Schrodinger on computational drug discovery

Ron Renaud on developing messenger RNA therapies.

Krishna Yeshwant of GV on life at the intersection of tech and biotech.

Ned David on extending human healthspan.

Julie Sunderland on VC investing at the nexus of tech and biotech.

Barbara Weber on synthetic lethal cancer drug discovery

John Wilbanks on making it easy to share biological data.

Sabah Oney on becoming a scientific business executive.

Amy Abernethy on making EHRs useful for drug development.

Meg Tirrell on covering biotech on TV.

Thong Le on building startups to suit pharma needs.

Ankit Mahadevia on the antibiotic opportunity

Chris Garabedian on the "middle market" of biotech VC.

Vicki Sato on her career in biotech.

Tony Coles on neurodegenerative drug discovery and inclusive leadership.

Ep20: Rob Perez by Timmerman Report

Ep19: Chip Clark by Timmerman Report

Ep18: Ethan Perlstein by Timmerman Report

Ep17: Alice Zhang by Timmerman Report

Michael Gilman on becoming an entrepreneur.

Bruce Booth on human capital

Agios CEO David Schenkein on building a cancer R&D engine to last.

Stephane Bancel, CEO of Moderna Therapeutics, on his influences.

Abbie Celniker of Third Rock Ventures on her career, and chipping away at gender inequities in biotech.

Bob More on biotech venture capital

Daniel Levine & Dan Maher discuss their book "A Rare Breed."

Steve Graham on racism in Corporate America.

Ep6: Steve Holtzman of Decibel Therapeutics on political activism among biotech CEOs.

Elias Zerhouni, president of R&D at Sanofi, on immigration in science and the importance of government science funding.

Alkermes CEO Richard Pops on fighting the opioid painkiller crisis.

Interview with Regeneron president and CSO George Yancopoulos

Ep. 2 of The Long Run With Luke Timmerman. Interview with Katrine Bosley, CEO of Editas Medicine.

Ep. 1 of The Long Run, a biotech podcast with Luke Timmerman. Conversation with Alnylam Pharmaceuticals CEO John Maraganore.